Cantor Fitzgerald analyst Charles Duncan raised the firm’s price target on Biohaven to $31 from $27 and keeps an Overweight rating on the shares. Biohaven’s cash balance should be sufficient to support operations into late-2024 and through key potential value-creating milestones, including the planned initiation of the P2/3 studies of BHV-7000 in focal epilepsy and bipolar disorder, guided for 2H23, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BHVN:
- Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
- Biohaven acquires rights to develop dual inhibitor of TYK2 and JAK1
- Biohaven to present anti-seizure results of BHV-7000
- Biohaven’s taldefgrobep alfa receives FDA Fast Track designation for SMA
